Precision Medicine Company adyn Raises $2.5M Seed Funding for Personalized Birth Control

22 Apr, 2021

Precision Medicine Company adyn Raises $2.5M Seed Funding for Personalized Birth Control
Photo by Dan Schiumarini on Unsplash

– adyn, a precision medicine company, announced today that it has closed a $2.5m seed round of funding.
– The round was co-led by Lux Capital and M13 with participation from Civilization Ventures, Concrete Rose Capital, Y Combinator, Madrona Pioneer Fund, Ascend VC, and angel investors including Anne Wojcicki of 23andMe, Nish Bhat of Color Genomics, Qasar Younis of Applied Intuition, and Ashley Mayer of Glossier.
– adyn uses proprietary hormone and genomic analyses to transform this selection process into a science and remove the guesswork.
– Using adyn’s precision medicine approach, patients and doctors will be able to personalize birth control selection, minimizing side effects ranging from annoyances like acne to life threatening conditions including blood clots and depression.

Biopharma Biotechnology Health Care Medical North America Pharmaceutical
Crunchbase icon

Content report

The following text will be sent to our editors: